• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

6-Nitro-1,2,3,4-Tetrahydro-Isoquinoline Hydrobromide: A Comprehensive Overview

6-Nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide, identified by the CAS number 1187932-26-8, is a significant compound in the field of organic chemistry and pharmacology. This compound belongs to the class of isoquinoline derivatives, which have garnered substantial attention due to their diverse biological activities and potential applications in drug discovery. The molecule's structure consists of a tetrahydroisoquinoline backbone with a nitro group at the 6-position and a hydrobromide counterion, making it a unique entity within its chemical family.

The synthesis of 6-nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide involves multi-step processes that often begin with the preparation of the parent tetrahydroisoquinoline compound. The introduction of the nitro group at the 6-position is typically achieved through nitration reactions, which require precise control over reaction conditions to ensure regioselectivity. The subsequent formation of the hydrobromide salt involves protonation of the nitrogen atom in the tetrahydroisoquinoline ring and subsequent treatment with hydrobromic acid. This process not only stabilizes the compound but also enhances its solubility in aqueous media, making it more amenable for pharmacological studies.

Recent advancements in chemical synthesis have enabled researchers to explore alternative routes for synthesizing 6-nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide. For instance, microwave-assisted synthesis has been employed to accelerate reaction rates and improve yields. Additionally, green chemistry principles have been integrated into these processes to minimize environmental impact and reduce waste generation.

The biological activity of 6-nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide has been extensively studied across various fields. In pharmacology, this compound has demonstrated potential as a modulator of ion channels and receptors involved in pain signaling pathways. Preclinical studies have highlighted its ability to inhibit voltage-gated sodium channels (Nav), which are critical for nerve impulse propagation. This property suggests its potential as a candidate for treating chronic pain conditions such as neuropathic pain.

In addition to its pharmacological applications, 6-nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide has also been investigated for its role in neuroprotection. Research indicates that this compound may exert neuroprotective effects by mitigating oxidative stress and reducing inflammation in neuronal cells. These findings underscore its potential utility in treating neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The structural versatility of 6-nitro-1,2,3,4-tetrahydro-isoquinoline hydrobromide has also made it an attractive scaffold for drug design. By modifying substituents on the isoquinoline ring or altering the nitro group's position or nature (e.g., replacing it with other functional groups), researchers can explore a wide range of biological activities and optimize pharmacokinetic properties such as bioavailability and metabolic stability.

From an analytical standpoint, modern techniques such as high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy have been instrumental in confirming the identity and purity of 6-nitro-1,2,3,tetrahydro-isoquinoline hydrobromide. These methods provide detailed insights into the compound's molecular structure and help ensure its quality for both research and potential therapeutic applications.

In conclusion, 6-nitro-1,tetrahydro isoquinoline hydrobromide, with its unique chemical structure and promising biological activities,cas no 1187932 26 8 stands at the forefront of contemporary chemical research. Its role as a lead compound in drug discovery highlights its significance in advancing treatments for various diseases while ongoing research continues to unlock new potentials within this fascinating molecule.

• 742679-30-7(Isoquinoline,1-ethyl-1,2,3,4-tetrahydro-7-nitro-)
• 208589-95-1(2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline)
• 186390-77-2(6-Nitro-1,2,3,4-tetrahydroisoquinoline)
• 99365-69-2(7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride)
• 174648-98-7(6-Nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride)
• 223915-75-1(8-Nitro-2,3,4,5-tetrahydro-1H-benzo[c]azepine)
• 42923-79-5(7-Nitro-1,2,3,4-tetrahydroisoquinoline)
• 791048-46-9(Isoquinoline,1,2,3,4-tetrahydro-1,3-dimethyl-7-nitro-, (1R,3R)-)
• 711601-13-7(2-Ethyl-7-nitro-1,2,3,4-tetrahydroisoquinoline)
• 14097-35-9(2-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline)